These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 14991949)

  • 21. [HCV RNA in PBMC as predictor of the response to antiviral therapy in chronic hepatitis C].
    Xu DZ; Li ZQ; Xie Y
    Zhonghua Gan Zang Bing Za Zhi; 2004 Feb; 12(2):76-8. PubMed ID: 14980103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sustained virological response to antiviral treatment in chronic hepatitis C patients may be predictable by HCV-RNA clearance in peripheral blood mononuclear cells.
    Coppola N; De Pascalis S; Pisaturo M; Paradiso L; Macera M; Capoluongo N; Alessio L; Stanzione M; Sagnelli C; Minichini C; Sagnelli E
    J Clin Virol; 2013 Dec; 58(4):748-50. PubMed ID: 24140030
    [No Abstract]   [Full Text] [Related]  

  • 23. HLA-A2-restricted cytotoxic T lymphocyte activity during interferon beta therapy in patients with chronic hepatitis C.
    Ohira H; Iwasaki M; Takiguchi J; Rai T; Shishido S; Abe K; Takeda J; Tojo J; Sato Y; Kasukawa R
    Fukushima J Med Sci; 2002 Dec; 48(2):75-83. PubMed ID: 12680611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mevalonate pathway modulation is associated with hepatitis C virus RNA presence in peripheral blood mononuclear cells.
    Sidorkiewicz M; Józwiak B; Durys B; Majda-Stanislawska E; Piekarska A; Kosciuk N; Ciechowicz J; Majewska E; Bartkowiak J
    Virus Res; 2009 Oct; 145(1):141-4. PubMed ID: 19540284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive factors for sustained response to interferon treatment in patients with chronic hepatitis C: a randomized, open, and multi-center controlled trial.
    Xie Y; Xu DZ; Lu ZM; Luo KX; Jia JD; Wang YM; Zhao GZ; Zhang SL; Zhang DZ
    Hepatobiliary Pancreat Dis Int; 2005 May; 4(2):213-9. PubMed ID: 15908318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Presence of HCV RNA in peripheral blood mononuclear cells may predict patients response to interferon and ribavirin therapy.
    Zaman N; Asad MJ; Raza A; Raja GK; Akhter S; Mahmood M; Mahmood RT
    Ann Saudi Med; 2014; 34(5):401-6. PubMed ID: 25827697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interferon treatment for patients with chronic hepatitis C infected with high viral load of genotype 2 virus.
    Nakamura H; Ogawa H; Kuroda T; Yamamoto M; Enomoto H; Kishima Y; Yoshida K; Ito H; Matsuda M; Noguchi S
    Hepatogastroenterology; 2002; 49(47):1373-6. PubMed ID: 12239945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitation of hepatitis C virus RNA in plasma and peripheral blood mononuclear cells of patients with chronic hepatitis treated with interferon-alpha.
    Trimoulet P; Bernard PH; de Ledinghen V; Oui B; Chene G; Saint-Marc Girardin MF; Dantin S; Couzigou P; Fleury H
    Dig Dis Sci; 2000 Jan; 45(1):175-81. PubMed ID: 10695632
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of interferon therapy on hepatitis C virus RNA in whole blood, plasma, and peripheral blood mononuclear cells.
    Schmidt WN; Wu P; Brashear D; Klinzman D; Phillips MJ; LaBrecque DR; Stapleton JT
    Hepatology; 1998 Oct; 28(4):1110-6. PubMed ID: 9755250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kinetics of the hepatitis C virus during interferon therapy as a marker of therapeutic response.
    Nakamuta M; Fukutomi T; Shimohashi N; Kinukawa N; Uchimura K; Tada S; Motomura K; Enjoji M; Kato M; Iwamoto H; Tanabe Y; Imari Y; Sakamoto S; Sakai H; Nawata H
    J Gastroenterol Hepatol; 2001 Jan; 16(1):29-33. PubMed ID: 11206312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Late disappearance of hepatitis C virus RNA from peripheral blood mononuclear cells in patients with chronic hepatitis C in sustained response after alpha-interferon therapy.
    García-Bengoechea M; Basaras M; Barrio J; Arrese E; Montalvo II; Arenas JI; Cisterna R
    Am J Gastroenterol; 1999 Jul; 94(7):1902-5. PubMed ID: 10406257
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of molecular parameters for routine assessment of viremia in patients with chronic hepatitis C who are undergoing antiviral therapy.
    Kessler HH; Pierer K; Santner BI; Vellimedu SK; Stelzl E; Marth E; Fickert P; Stauber RE
    J Hum Virol; 1998; 1(5):314-9. PubMed ID: 10195258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid clearance of hepatitis C virus RNA in peripheral blood mononuclear cells of patients with clotting disorders and chronic hepatitis C treated with alpha-2b interferon is not a predictor for sustained response to treatment.
    Peerlinck K; Willems M; Sheng L; Nevens F; Fevery J; Yap SH; Vermylen J
    Br J Haematol; 1994 Apr; 86(4):816-9. PubMed ID: 7918078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genome detection in liver and peripheral blood mononuclear cells: predictor factors of sustained response in patients with chronic hepatitis C.
    Berenguer M; Olaso V; Córdoba J; Gobernado M; Carrasco D; Berenguer J
    Eur J Gastroenterol Hepatol; 1995 Sep; 7(9):899-903. PubMed ID: 8574725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection.
    Furusyo N; Hayashi J; Ohmiya M; Sawayama Y; Kawakami Y; Ariyama I; Kinukawa N; Kashiwagi S
    Dig Dis Sci; 1999 Mar; 44(3):608-17. PubMed ID: 10080158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders.
    Watanabe S; Kobayashi Y; Kawata K; Noritake H; Chida T; Nagasawa M; Kageyama F; Kawamura K; Sasada Y; Suda T
    Intern Med; 2015; 54(3):273-9. PubMed ID: 25748735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of virus genotype on interferon treatment of patients with chronic hepatitis C: a multicenter controlled study.
    Xie Y; Xu DZ; Lu ZM; Luo KX; Jia JD; Wang YM; Zhao GZ; Zhang SL; Zhang DZ
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):369-74. PubMed ID: 15313671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro effect of amantadine and interferon alpha-2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus-infected patients.
    Martín J; Navas S; Fernández M; Rico M; Pardo M; Quiroga JA; Zahm F; Carreño V
    Antiviral Res; 1999 May; 42(1):59-70. PubMed ID: 10333143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Twice-daily administration of interferon-beta for chronic hepatitis C is not superior to a once-daily regimen.
    Suzuki F; Chayama K; Tsubota A; Akuta N; Someya T; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Gastroenterol; 2001 Apr; 36(4):242-7. PubMed ID: 11324727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peripheral blood mononuclear cells microRNA predicts treatment outcome of hepatitis C virus genotype 1 infection.
    Hsi E; Huang CF; Dai CY; Juo SH; Chou WW; Huang JF; Yeh ML; Lin ZY; Chen SC; Wang LY; Chuang WL; Yu ML
    Antiviral Res; 2014 May; 105():135-42. PubMed ID: 24637254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.